Complement factors and acute phase reactants in the Guillain-Barré syndrome.
The concentrations of C3, C4, C1 inactivator, C3 proactivator and orosomucoid were determined in sera from 13 patients with Guillain-Barré syndrome. The most severely affected patients had the highest levels of C3, C4 and orosomucoid in the acute phase with a slight decline over the following 3-8 weeks. The mildly affected patients had complement concentrations in the upper normal range. In the group of patients with the highest concentrations of C3, C4 and orosomucoid, 4 out of 6 developed residual weakness, while residual weakness was only found in 1 out of 7 with normal concentrations. The measurement of C3 and C4 may, therefore, be of value in estimating the severity and prognosis in the early phase of the disease.
D000293:Adolescent; D000328:Adult; D000368:Aged; D003166:Complement Activating Enzymes / Q000032:analysis*; D003174:Complement C1 Inactivator Proteins / Q000032:analysis*; D003176:Complement C3 / Q000032:analysis; D050577:Complement C3-C5 Convertases / Q000032:analysis*; D003181:Complement C4 / Q000032:analysis; D003165:Complement System Proteins / Q000032:analysis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009961:Orosomucoid / Q000032:analysis*; D011129:Polyradiculoneuropathy / Q000276:immunology*; D011379:Prognosis
D003174:Complement C1 Inactivator Proteins; D003176:Complement C3; D003181:Complement C4; D009961:Orosomucoid; D003165:Complement System Proteins; D003166:Complement Activating Enzymes; D050577:Complement C3-C5 Convertases